Skin thickness in children treated with daily or periodical inhaled budesonide for mild persistent asthma. The Helsinki early intervention childhood asthma study.
In adults, asthma treatment with high doses of inhaled corticosteroids has resulted in dermal thinning. The aim of this study was to investigate the skin thickness in children with asthma during budesonide treatment. In a double-blind study, 113 children, 5-10 y old, with persistent asthma received budesonide 400 microg twice daily for 1 mo and thereafter 200 microg twice daily for 5 mo. Thereafter, 56 children received 100 microg twice daily for 1 y, whereas 57 other children used budesonide periodically for exacerbations. An additional 54 children were treated with disodium cromoglycate (DSCG) for 18 mo. Skin thickness was measured on each forearm before and after treatment for 6, 12, and 18 mo using a 20-MHz high-resolution ultrasonic device. The initial 6-mo budesonide treatment resulted in a greater reduction in mean skin thickness in the forearms compared with DSCG (right: -35.9 versus -5.9 microm; p = 0.004; left: -30.6 versus -7.3 microm; p = 0.03). At month 18, the inter-group differences were no longer significant. Budesonide inhalations in daily doses of 400-800 microg in prepubertal children with newly detected asthma may cause minor dermal thinning. The changes were reversible during low dose or periodic treatment with budesonide.
Turpeinen
Markku
M
Department of Allergy, Helsinki University Central Hospital, Meilahdentie 2, FIN-00250 Helsinki, Finland. markku.t.turpeinen@hus.fi
Raitio
Hanna
H
Pelkonen
Anna S
AS
Nikander
Kurt
K
Sorva
Ritva
R
Selroos
Olof
O
Juntunen-Backman
Kaisu
K
Haahtela
Tari
T
D000280:Administration, Inhalation; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001249:Asthma / Q000188:drug therapy*; D001284:Atrophy; D001993:Bronchodilator Agents / Q000008:administration & dosage* / Q000009:adverse effects; D019819:Budesonide / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D004205:Cromolyn Sodium / Q000008:administration & dosage; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005387:Finland; D005542:Forearm; D006801:Humans; D008297:Male; D012720:Severity of Illness Index; D012867:Skin / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000473:pathology; D012885:Skinfold Thickness; D013997:Time Factors; D016896:Treatment Outcome; D014463:Ultrasonography
D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D019819:Budesonide; D004205:Cromolyn Sodium